The changes would limit how insurers add patient diagnoses that trigger lucrative extra payments.

A month has gone by since the last earnings report for Humana (HUM). Shares have lost about 10.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to ...

Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE:HUM) and a $313 price target. The ...

HealthEquity (HQY) reports strong Q1 2026 growth with increased revenue, reduced fraud costs, and advancements in AI and mobile tech.

Humana said it is reaffirming its prior 2025 EPS guidance. The health insurer sees $14.68 in diluted EPS or $16.25 in ...